BRAF inhibitor–induced necrotizing granulomatous lymphadenopathy: a case report of drug-induced sarcoid-like reaction

BRAF inhibitors are a class of targeted therapies used in the treatment of malignant melanoma. They are the standard of care in the treatment of advanced BRAF-mutated malignant melanoma and are generally well tolerated. However, in rare cases, an adverse effect involving granulomatous lymphadenopathy may occur. This case report discusses a patient receiving BRAF inhibitor therapy who developed mediastinal lymphadenopathy with necrotizing granulomatous disease found on intranodal forceps biopsy.